262 related articles for article (PubMed ID: 17912451)
1. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
Sotomayor S; Carmena MJ; Schally AV; Varga JL; Sánchez-Chapado M; Prieto JC; Bajo AM
Int J Oncol; 2007 Nov; 31(5):1223-30. PubMed ID: 17912451
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells.
Valdehita A; Bajo AM; Schally AV; Varga JL; Carmena MJ; Prieto JC
Mol Cell Endocrinol; 2009 Apr; 302(1):41-8. PubMed ID: 19101605
[TBL] [Abstract][Full Text] [Related]
3. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines Differential time-dependent responses in cancer progression.
Fernández-Martínez AB; Collado B; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ
Mol Cell Endocrinol; 2007 May; 270(1-2):8-16. PubMed ID: 17434257
[TBL] [Abstract][Full Text] [Related]
6. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
[TBL] [Abstract][Full Text] [Related]
7. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.
Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ
Prostate; 2009 May; 69(7):774-86. PubMed ID: 19189304
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K.
Gutiérrez-Cañas I; Juarranz MG; Collado B; Rodríguez-Henche N; Chiloeches A; Prieto JC; Carmena MJ
Prostate; 2005 Apr; 63(1):44-55. PubMed ID: 15468165
[TBL] [Abstract][Full Text] [Related]
9. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
Rekasi Z; Varga JL; Schally AV; Halmos G; Armatis P; Groot K; Czompoly T
Endocrinology; 2000 Jun; 141(6):2120-8. PubMed ID: 10830299
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity.
Plonowski A; Varga JL; Schally AV; Krupa M; Groot K; Halmos G
Int J Cancer; 2002 Apr; 98(4):624-9. PubMed ID: 11920625
[TBL] [Abstract][Full Text] [Related]
11. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia regulation of expression and angiogenic effects of vasoactive intestinal peptide (VIP) and VIP receptors in LNCaP prostate cancer cells.
Collado B; Sánchez-Chapado M; Prieto JC; Carmena MJ
Mol Cell Endocrinol; 2006 Apr; 249(1-2):116-22. PubMed ID: 16563610
[TBL] [Abstract][Full Text] [Related]
13. Multifunctional role of VIP in prostate cancer progression in a xenograft model: suppression by curcumin and COX-2 inhibitor NS-398.
Fernández-Martínez AB; Bajo AM; Valdehita A; Isabel Arenas M; Sánchez-Chapado M; Carmena MJ; Prieto JC
Peptides; 2009 Dec; 30(12):2357-64. PubMed ID: 19772879
[TBL] [Abstract][Full Text] [Related]
14. Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog.
Collado B; Carmena MJ; Sánchez-Chapado M; Ruíz-Villaespesa A; Bajo AM; Fernández-Martínez AB; Varga JL; Schally AV; Prieto JC
Int J Oncol; 2005 Jun; 26(6):1629-35. PubMed ID: 15870879
[TBL] [Abstract][Full Text] [Related]
15. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
16. Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat.
Laburthe M; Couvineau A; Rouyer-Fessard C
Mol Pharmacol; 1986 Jan; 29(1):23-7. PubMed ID: 3003561
[TBL] [Abstract][Full Text] [Related]
17. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.
Nagasawa J; Mizokami A; Koshida K; Yoshida S; Naito K; Namiki M
Int J Urol; 2006 May; 13(5):587-92. PubMed ID: 16771730
[TBL] [Abstract][Full Text] [Related]
18. Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells.
Valdehita A; Carmena MJ; Collado B; Prieto JC; Bajo AM
Regul Pept; 2007 Dec; 144(1-3):101-8. PubMed ID: 17683807
[TBL] [Abstract][Full Text] [Related]
19. Regulation of cyclooxygenase-2 pathway by HER2 receptor.
Vadlamudi R; Mandal M; Adam L; Steinbach G; Mendelsohn J; Kumar R
Oncogene; 1999 Jan; 18(2):305-14. PubMed ID: 9927187
[TBL] [Abstract][Full Text] [Related]
20. RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells.
Valdehita A; Carmena MJ; Bajo AM; Prieto JC
Mol Cell Endocrinol; 2012 Jan; 348(1):241-6. PubMed ID: 21896307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
